Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma

Research output: Contribution to journalReview article

Abstract

Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.

Original languageEnglish (US)
JournalPET Clinics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Fluorodeoxyglucose F18
Multiple Myeloma
tomography
Bone Marrow
Tomography
evaluation
bone marrow
Residual Neoplasm
Hematologic Neoplasms
Plasma Cells
Neoplasms
Therapeutics
tumors
cells

Keywords

  • Extramedullary disease
  • Minimal residual disease
  • Multiple myeloma
  • PET
  • PET/CT
  • Response

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

@article{27240d23a6f34d1a95515580948ce6e1,
title = "Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma",
abstract = "Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.",
keywords = "Extramedullary disease, Minimal residual disease, Multiple myeloma, PET, PET/CT, Response",
author = "Kumar, {Shaji K} and Glazebrook, {Katrina Nesta} and Stephen Broski",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cpet.2019.03.006",
language = "English (US)",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma

AU - Kumar, Shaji K

AU - Glazebrook, Katrina Nesta

AU - Broski, Stephen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.

AB - Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.

KW - Extramedullary disease

KW - Minimal residual disease

KW - Multiple myeloma

KW - PET

KW - PET/CT

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=85064073468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064073468&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2019.03.006

DO - 10.1016/j.cpet.2019.03.006

M3 - Review article

C2 - 31084778

AN - SCOPUS:85064073468

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

ER -